Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8026 to 8040 of 8578 results

  1. Vandetanib for treating metastatic, differentiated thyroid cancer refractory to or unsuitable for radioiodine therapy [ID907]

    Discontinued Reference number: GID-TA11259

    Technology appraisal guidance
    Discontinued

  2. Bone metastases (hormone refractory prostate cancer) - denosumab [ID405]

    Discontinued Reference number: GID-TAG300

    Technology appraisal guidance
    Discontinued

  3. Heart failure (acute decompensated) - nesiritide [ID384]

    Discontinued Reference number: GID-TAG376

    Technology appraisal guidance
    Discontinued

  4. Sacubitril valsartan for treating chronic heart failure with preserved ejection fraction [ID1606]

    Discontinued Reference number: GID-TA11257

    Technology appraisal guidance
    Discontinued

  5. Venous thromboembolism (recurrent) - idraparinux sodium [ID395]

    Discontinued Reference number: GID-TAG384

    Technology appraisal guidance
    Discontinued

  6. Multiple sclerosis (primary-progressive) - fingolimod [ID62]

    Discontinued Reference number: GID-TAG221

    Technology appraisal guidance
    Discontinued

  7. Canakinumab and tocilizumab for treating systemic juvenile idiopathic arthritis [ID983]

    Discontinued Reference number: GID-TA11241

    Technology appraisal guidance
    Discontinued

  8. Capecitabine for the treatment of advanced pancreatic cancer [ID127]

    Discontinued Reference number: GID-TA11239

    Technology appraisal guidance
    Discontinued

  9. Masitinib for previously treated moderate Crohn's disease [ID1239]

    Discontinued Reference number: GID-TA11188

    Technology appraisal guidance
    Discontinued

  10. Multiple myeloma (untreated) - carfilzomib (with melphalan and prednisone) [ID1133]

    Discontinued Reference number: GID-TA11210

    Technology appraisal guidance
    Discontinued

  11. Ovarian (epithelial), fallopian, peritoneal cancer - paclitaxel (encapsulated in XR-17 [ID565]

    Discontinued Reference number: GID-TA11209

    Technology appraisal guidance
    Discontinued

  12. Lymphoma (diffuse large B-cell, untreated) – liposomal vincristine [ID1123]

    Discontinued Reference number: GID-TA11208

    Technology appraisal guidance
    Discontinued

  13. Lymphoma (non Hodgkin's) - bendamustine (with rituximab) [ID434]

    Discontinued Reference number: GID-TAG278

    Technology appraisal guidance
    Discontinued

  14. Cetuximab for the treatment of advanced non-small-cell lung cancer [ID9]

    Discontinued Reference number: GID-TAG395

    Technology appraisal guidance
    Discontinued

  15. Intensity modulated radiotherapy for breast cancer [ID16]

    Discontinued Reference number: GID-TAG390

    Technology appraisal guidance
    Discontinued